Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Single Arm, Open-label Phase 1/2 Clinical Trial to Evaluate Safety, and to Explore Efficacy of TC011(CD19 Targeted CAR-T) in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients

NCT07473167 is registered in ClinicalTrials.gov with TICAROS Co., Ltd. as lead sponsor.

NCT NCT07473167
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07473167 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Single Arm, Open-label Phase 1/2 Clinical Trial to Evaluate Safety, and to Explore Efficacy of TC011(CD19 Targeted CAR-T) in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients
Lead sponsor
TICAROS Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 3, 2023
Completion date
March 10, 2028
Enrollment
98 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma (dlbcl), high-grade b-cell lymphoma (hgbl), primary mediastinal large b-cell lymphoma (pmbcl), refractory large b-cell lymphoma, relapsed large b-cell lymphoma, transformed follicular lymphoma (tfl)